incretin-like effects of small molecule trace amine-associated receptor 1 agonists

Clicks: 406
ID: 142326
2016
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #17 of 95 articles by views in Small (Weinheim an der Bergstrasse, Germany)

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Objective: Type 2 diabetes and obesity are emerging pandemics in the 21st century creating worldwide urgency for the development of novel and safe therapies. We investigated trace amine-associated receptor 1 (TAAR1) as a novel target contributing to the control of glucose homeostasis and body weight. Methods: We investigated the peripheral human tissue distribution of TAAR1 by immunohistochemistry and tested the effect of a small molecule TAAR1 agonist on insulin secretion in vitro using INS1E cells and human islets and on glucose tolerance in C57Bl6, and db/db mice. Body weight effects were investigated in obese DIO mice. Results: TAAR1 activation by a selective small molecule agonist increased glucose-dependent insulin secretion in INS1E cells and human islets and elevated plasma PYY and GLP-1 levels in mice. In diabetic db/db mice, the TAAR1 agonist normalized glucose excursion during an oral glucose tolerance test. Sub-chronic treatment of diet-induced obese (DIO) mice with the TAAR1 agonist resulted in reduced food intake and body weight. Furthermore insulin sensitivity was improved and plasma triglyceride levels and liver triglyceride content were lower than in controls. Conclusions: We have identified TAAR1 as a novel integrator of metabolic control, which acts on gastrointestinal and pancreatic islet hormone secretion. Thus TAAR1 qualifies as a novel and promising target for the treatment of type 2 diabetes and obesity.
Reference Key
raab2016molecularincretin-like Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Susanne Raab;Haiyan Wang;Sabine Uhles;Nadine Cole;Ruben Alvarez-Sanchez;Basil Künnecke;Christoph Ullmer;Hugues Matile;Marc Bedoucha;Roger D. Norcross;Nickki Ottaway-Parker;Diego Perez-Tilve;Karin Conde Knape;Matthias H. Tschöp;Marius C. Hoener;Sabine Sewing
Journal Small (Weinheim an der Bergstrasse, Germany)
Year 2016
DOI
10.1016/j.molmet.2015.09.015
URL
http://www.sciencedirect.com/science/article/pii/S2212877815002008
Keywords
type 2 diabetes incretin hormones insulin secretion

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.